Myelodysplastic syndrome: An update on diagnosis and therapy

Current Oncology Reports

Volumn 10, Issue 5, 2008, Pages 372-378

  Koppel, Ahrin ^a   Schiller, Gary ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; CYCLOSPORIN; CYTARABINE; ETANERCEPT; GROWTH FACTOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; THALIDOMIDE; THYMOCYTE ANTIBODY; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; APOPTOSIS; BLEEDING; BLOOD ANALYSIS; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW BIOPSY; BONE MARROW DEPRESSION; CANCER RISK; CANCER SURVIVAL; CELL CLONING; CELL DIFFERENTIATION; CELL MATURATION; CELL STRUCTURE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; CYTOGENETICS; CYTOLOGY; CYTOPENIA; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EPIGENETICS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INFECTION; LABORATORY TEST; LEUKOPENIA; LIFE EXPECTANCY; LOW DRUG DOSE; MALIGNANT TRANSFORMATION; MORBIDITY; MORTALITY; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PATHOPHYSIOLOGY; PHENOTYPE; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; REFRACTORY ANEMIA WITH EXCESS BLASTS; REVIEW; SCORING SYSTEM; SKIN MANIFESTATION; STRUCTURE ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION; AGED; FEMALE; GENETIC EPIGENESIS; GENETICS; HEMATOLOGY; KARYOTYPING; LEUKEMIA; MALE; METHODOLOGY; MIDDLE AGED; ONCOLOGY; TREATMENT OUTCOME;

AGED; CYTOGENETICS; EPIGENESIS, GENETIC; FEMALE; HEMATOLOGY; HUMANS; KARYOTYPING; LEUKEMIA; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TREATMENT OUTCOME;

EID: 55749098803     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0058-z     Document Type: Review

References (49)

1. Bennett JM, Catovsky D, Daniel MT: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51: 189-199.
2. Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17: 3835-3849.
3. Aul C, Giagounidis A, Germing U: Epidemiological features of myelodysplastic syndromes: Results from regional cancer surveys and hospital-based statistics. Int J Hematol 2001, 73: 405-410.
4. Mathew P, TAfferi A, Dewald GW, et al.: The 5q-syndrome: a single-institution study of 43 consecutive patients. Blood 1993, 81: 1040-1045.
5. Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89: 2079-2088. Erratum in: Blood 1998, 91: 1100.
6. Billström R, Johansson H, Johansson B, Mitelman F: Immune-mediated complications in patients with myelodysplastic syndromes: Clinical and cytogenetic features. Eur J Haematol 1995, 55: 42-48.
7. Chandran G, Ahern MJ, Seshadri P, Coghlan D: Rheumatic manifestations of the myelodysplastic syndromes: A comparative study. Aust N Z J Med 1996, 26: 683-688.
8. Enright H, Jacob HS, Vercellotti G, et al.: Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: Response to immunosuppressive therapy. Br J Haematol 1995, 91: 403-408.
9. Saif MW, Hopkins JL, Gore SD: Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 2002, 43: 2083-2092.
10. Tefferi A, Hoagland HC, Therneau TM, Pierre RV: Chronic myelomonocytic leukemia: Natural history and prognostic determinants. Mayo Clin Proc 1989, 64: 1246-1254.
11. Soppi E, Nousiainen T, Seppa A, Lahtinen R: Acute febrile neutrophilic dermatosis (Sweet's syndrome) in association with myelodysplastic syndromes: A report of three cases and a review of the literature. Br J Haematol 1989, 73: 43-47.
12. French registry of acute leukemia and myelodysplastic syndromes. Age distribution and hemogram analysis of the 4496 cases recorded during 1982-1983 and classified according to FAB criteria. Groupe Francais de Morphologie Hematologique. Cancer 1987, 60: 1385-1394.
13. Bowen D, Culligan D, Jowitt S, et al.: Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003, 120: 187-200.
14. Michels SD, McKenna RW, Arthur DC, et al.: Therapy-related acute myeloid leukemia and myelodysplastic syndrome: A clinical and morphologic study of 65 cases. Blood 1985, 65: 1364-1372.
15. Horny HP, Sotlar K, Valent P: Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res 2007, 31: 1609-1616.
16. Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen RL: Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 1984, 58: 217-225.
17. Oriani A, Annaloro C, Soligo D, et al.: Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes. Br J Haematol 1996, 92: 360-364.
18. Panani AD, Roussos C: Cytogenetic aspects of adult primary myelodysplastic syndromes: Clinical implications. Cancer Lett 2006, 235: 177-190.
19. Bernasconi P, Alessandrino EP, Boni M, et al.: Karyotype in myelodysplastic syndromes: Relations to morphology, clinical evolution, and survival. Am J Hematol 1994, 46: 270-277.
20. de Souza Fernandez T, Ornellas MH, Otero de Carvalho L, et al.: Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. Leuk Res 2000, 24: 839-848.
21. Valent P, Horny HP, Bennett JM, et al.: Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007, 31: 727-736.
22. Haase D, Germing U, Schanz J, et al.: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007, 110: 4385-4395.
23. Garcia-Manero G: Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology Am Soc Hematol Educ Program 2007, 405-411.
24. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 49: 2042-2054.
25. Lubbert M: DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 2000, 249: 135-164.
26. Daskalakis M, Nguyen TT, Nguyen C, et al.: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2'-deoxycytidine (decitabine) treatment. Blood 2002, 100: 2957-2964.
27. Uchida T, Kinoshita T, Nagai H, et al.: Hypermethylation of the p15/ INK4B gene in myelodysplastic syndromes. Blood 1997, 4: 1403-1409.
28. Quesnel B, Guillerm G, Vereecque R, et al.: Methylation of the p15/INK4B gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998, 8: 2985-2990.
29. Ebert BL, Pretz J, Bosco J, et al.: Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008, 451: 335-339.
30. Mohamedali A, Gäken J, Twine NA, et al.: Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007, 110: 3365-3373.
31. Cheson BD, Bennett JM, Kantarjian H, et al.: World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96: 3671-3674.
32. Cheson BD, Greenberg PL, Bennett JM, et al.: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108: 419-425.
33. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in oncology: Myelodysplastic syndromes. Available at http://www.nccn.org. Accessed April 2008.
34. Aul C, Schneider W: The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 1989, 64: 1812-1818.
35. Oosterveld M, Wittebol SH, Lemmens WA, et al.: The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups. Br J Haematol 2003, 123: 81-89.
36. Saunthararajah Y, Nakamura R, Nam JM, Robyn J: HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002, 100: 1570-1574.
37. Jonásova A, Neuwirtová R, Cermák J, et al.: Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998, 100: 304-309.
38. Appelbaum FR, Anderson J: Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score. Leukemia 1998, 12(Suppl 1): S25-S29.
39. Anderson JE, Appelbaum FR, Fisher LD, et al.: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993, 82: 677-681.
40. Runde V, de Witte T, Arnold R, et al.: Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998, 21: 255-261.
41. Silverman LR, Demakos EP, Peterson BL, et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 2002, 20: 2429-2440.
42. Kornblith AB, Herndon JE II, Silverman LR, et al.: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study. J Clin Oncol 2002, 20: 2441-2452.
43. Kantarjian H, Issa JP, Rosenfeld CS, et al.: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006, 106: 1794-1803.
44. Saba HI, Wijermans PW: Decitabine in myelodysplastic syndromes. Semin Hematol 2005, 42(3 Suppl 2): S23-S31.
45. Bartlett JB, Dredge K, Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004, 4: 314-322.
46. List A, Dewald G, Bennett J, et al.: Myelodysplastic Syndrome-003 Study Investigators: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355: 1456-1465.
47. List AF, Dewald G, Bennett J, et al.: Clinical benefit from 2 phase II trials evaluating lenalidomide (REVLIMID) in lower-risk myelodysplastic syndrome patients with or without del 5q cytogenetic abnormalities [abstract 1032]. Presented at the 11th Congress of the European Hematology Association; June 15-18, 2006; Amsterdam, The Netherlands.
48. List A, Kurtin S, Roe DJ, et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352: 549-557.
49. Kuendgen A, Strupp C, Aivado M, et al.: Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004, 104: 1266-1269.